Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab plus trastuzumab and chemotherapy as adjuvant therapy in HER2-positive early breast cancer
jRCT2080221752Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Pertuzumab + trastuzumab + chemotherapy with Placebo + trastuzumab + chemotherapy (2 arms). Started Mar 2012; status: completed.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080221752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221752.